Latest Hotspot

Ajax Therapeutics Gains FDA Approval for New Myelofibrosis Drug AJ1-11095

15 May 2024
3 min read

Ajax Therapeutics, Inc., a company focused on biopharmaceuticals, has been granted approval from the U.S. Food and Drug Administration for its Investigational New Drug application, paving the way for a Phase I clinical trial of AJ111095. This novel Type II JAK2 inhibitor is being developed primarily for the treatment of individuals suffering from myelofibrosis, as part of the company's advanced research into JAK inhibitors aimed at addressing myeloproliferative neoplasms.

👇Unlock in-depth information about this drug - its R&D Status, Core Patent, Clinical Trials, and Global Approval Status. Click on the image below and explore the latest data immediately.

图形用户界面, 文本, 应用程序

描述已自动生成

Martin Vogelbaum, co-founder and CEO of Ajax Therapeutics, expressed his enthusiasm about the progression of AJ1-11095 into clinical trials, stating, "It's exhilarating to have the green light to move AJ1-11095 into clinical settings, offering hope with this novel therapeutic for those suffering from myelofibrosis.” He added, This represents a significant achievement for Ajax Therapeutics as it marks both our inaugural clinical entry and the maiden clinical investigation to assess a Type II JAK2 inhibitor in this patient population."

David Steensma, MD, FACP, and Chief Medical Officer at Ajax, shared his anticipation for the future trials: “We are eager to commence the clinical trials for AJ1-11095 in myelofibrosis, specifically starting with the Phase 1 dose escalation study, AJX-101, scheduled for later this year.” He elaborated on the drug’s potential, noting, “AJ1-11095 introduces a groundbreaking approach as a Type II JAK2 inhibitor. It was specifically engineered to bring a superior option to the myelofibrosis treatments currently available, potentially enhancing efficacy and altering the course of the disease.”

👇Explore the most recent advancements in drug research, indications, organizations, clinical trials, results, and patents related to this target by clicking the image link below. Dive in to gain deeper insights!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

According to the data provided by the Synapse Database, As of May 14, 2024, there are 68 investigational drugs for the JAK2 targets, including 222 indications, 137 R&D institutions involved, with related clinical trials reaching 1505, and as many as 9955 patents.

AJ1-11095 was designed to be a next generation JAK2 inhibitor by using structure-based drug design and computational methods at scale to selectively bind the Type II conformation of the JAK2 kinase and to provide greater efficacy with disease modification compared to all currently approved JAK2 inhibitors which bind the Type I conformation of JAK2. The drug's progression to higher phases of clinical development will provide more insights into its potential as a treatment option for patients with myelofibrosis and other related conditions.

图形用户界面, 文本, 网站

描述已自动生成

FDA Prioritizes Review of Dupixent® for Teen Chronic Sinusitis and Nasal Polyps
Latest Hotspot
3 min read
FDA Prioritizes Review of Dupixent® for Teen Chronic Sinusitis and Nasal Polyps
15 May 2024
FDA grants priority review to Dupixent® (dupilumab) sBLA for treating teens with chronic rhinosinusitis and nasal polyps.
Read →
Promising Phase 2a Results for Cardurion's Heart Failure Treatment
Latest Hotspot
3 min read
Promising Phase 2a Results for Cardurion's Heart Failure Treatment
15 May 2024
Cardurion Pharmaceuticals Reports Encouraging Outcomes from Phase 2a CARDINAL-HF Study of PDE9 Inhibitor in Heart Failure Patients.
Read →
AnaptysBio Announces Positive Early Results from Phase 3 GEMINI-2 Study of Imsidolimab for Generalized Pustular Psoriasis
Latest Hotspot
3 min read
AnaptysBio Announces Positive Early Results from Phase 3 GEMINI-2 Study of Imsidolimab for Generalized Pustular Psoriasis
14 May 2024
Anaptys released encouraging initial outcomes from the GEMINI-2 Phase 3 study of Imsidolimab (IL-36R) for treating Generalized Pustular Psoriasis.
Read →
First Wave BioPharma: Focused on Targeted Oral Therapies for Gastrointestinal Diseases
R&D Pipeline
4 min read
First Wave BioPharma: Focused on Targeted Oral Therapies for Gastrointestinal Diseases
14 May 2024
First Wave will concentrate on advancing a portfolio of gastrointestinal disease therapies, including latiglutenase, which encompasses multiples late-stage clinical assets.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.